Statins and the Liver
Copyright policy )Statins and the Liver
Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.
- Harborview Medical Center United States
- Veterans Health Administration United States
- University of Washington United States
- Washington University in St. Louis United States
- University of Mary United States
Liver, Cardiovascular Diseases, Risk Factors, Incidence, Liver Diseases, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Global Health, Lipids, Transaminases
Liver, Cardiovascular Diseases, Risk Factors, Incidence, Liver Diseases, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Global Health, Lipids, Transaminases
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).14 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!